RESUMO
A young man presented with haemoptysis, eight years after foreign body aspiration. The initial evaluation took place in the emergency department of a general hospital. However, neither chest x-ray nor bronchoscopy were performed. Bronchoscopy performed in our hospital revealed a foreign body in right lower lobe bronchus. Extraction failed because it was embedded in granulation tissue. The chronic atelectasis of right lower lobe and recurrent bronchopulmonary infections during the last years were the indication for lobectomy.
Assuntos
Brônquios/diagnóstico por imagem , Broncoscopia/métodos , Corpos Estranhos/diagnóstico por imagem , Hemoptise/etiologia , Pneumonectomia , Atelectasia Pulmonar/diagnóstico por imagem , Atelectasia Pulmonar/cirurgia , Humanos , Masculino , Atelectasia Pulmonar/etiologia , Traqueia , Resultado do TratamentoRESUMO
OBJECTIVES: Evaluation of a standardised management for the treatment of patients with parapneumonic empyema. METHODS: A retrospective 10-year single-centre analysis of all patients with parapneumonic empyema undergoing a standardised thoracoscopic treatment approach. We describe referral and age patterns, microbiological results, overall and stage-dependent success rates, conversion rates, 30-day and in-hospital mortality. RESULTS: From May 2003 to April 2013, 248 patients with parapneumonic empyemas were treated in our centre. Most patients were referred at weekends, and younger patients had advanced stages. The cure rate in stage I was 97.6â% and reached 80.3â% in stage II and 63.1â% in stage III. 6 patients (2.4â%) (all stage III) needed conversion to an open procedure. A revision was required in 19.7â% of cases in stage II and 27.7â% in stage III. 30-day mortality was 4.8â%, in-hospital mortality was 8.1â%. CONCLUSION: A standardised approach, including VATS, is associated with a high cure, low revision and moderate conversion rates. In view of a still considerable mortality, a higher index of suspicion and detection of advanced stages, especially in younger patients, is required to improve outcomes.
Assuntos
Empiema/cirurgia , Cirurgia Torácica Vídeoassistida , Toracostomia , Empiema/mortalidade , Alemanha/epidemiologia , Mortalidade Hospitalar , Humanos , Tempo de Internação , Masculino , Derrame Pleural/cirurgia , Estudos Retrospectivos , Resultado do TratamentoRESUMO
Flexible bronchoscopy is one of the most important diagnostic procedures in respiratory medicine. The investigator operates in a vital organ and therefore must face a broad range of potential complications. This article provides an overview of all important complications associated with flexible bronchoscopy. It is further discussed how this risk can be minimized. A skillfull team, close monitoring and readily available resuscitation facilities are mandatory to avoid and to deal with major complications.
Assuntos
Broncoscopia/efeitos adversos , Broncoscopia/métodos , Gestão de Riscos/métodos , Anestesia Local , Lavagem Broncoalveolar/efeitos adversos , Lavagem Broncoalveolar/métodos , Humanos , Equipe de Assistência ao Paciente , Doenças Respiratórias/diagnóstico , Ressuscitação/métodos , Fatores de RiscoRESUMO
Uroplakins are specific differentiation products of terminally differentiated superficial urothelial cells. We tested the value of a new commercially available monoclonal antibody against uroplakin III (clone AU 1) as a paraffin-reactive immunohistochemical marker for primary and metastatic urothelial carcinomas. The study cases included 67 urothelial carcinomas of the urinary tract (35 primary tumors, 32 metastases) and 318 nonurothelial carcinomas, as well as 5 benign Brenner tumors and 2 transitional cell carcinomas of the ovaries. Uroplakin III was detected in 21 (60%) of the primary urothelial carcinomas and 17 (53%) of the metastases, resulting in an overall sensitivity of 0.57. The studied Brenner tumors also were immunoreactive for uroplakin III. All other studied carcinomas were consistently uroplakin III-negative (specificity 1.00). We found the new monoclonal antibody AU 1 against uroplakin III to be a highly specific paraffin-reactive immunohistochemical marker for urothelial tumors with a moderate sensitivity for the identification of primary and metastatic urothelial carcinomas.